broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K54997624-001-06-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.203878 | 1.782854 | 0.773626 | 0.731235 | 0.378323 | 0.507539 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000909 |
BRD-K55187425-236-05-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.856447 | 2.64196 | 0.043033 | 0.886926 | 0.004781 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000909 |
BRD-K56343971-001-14-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.091464 | -0.169768 | -0.020578 | 1 | 1.755047 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000909 |
BRD-K56981171-001-02-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.917583 | -0.120651 | -0.096292 | 0.957923 | 0.111866 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000909 |
BRD-K57169635-001-04-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.131576 | 1.430827 | 0.190135 | 0.957249 | 10.135537 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000909 |
BRD-K58435339-001-03-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.308162 | 11.77847 | 0.677226 | 0.753299 | 0.314125 | 0.340738 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000909 |
BRD-K58529924-001-01-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.809596 | -4.238204 | 0.112768 | 0.891295 | 0.164754 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000909 |
BRD-K58550667-001-08-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.182919 | 6.001736 | 0.606682 | 0.718085 | 0.021959 | 0.02369 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000909 |
BRD-K59317601-001-05-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.20657 | 0.570577 | 0.672205 | 0.499914 | 0.018278 | 0.046516 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000909 |
BRD-K59369769-001-22-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.322533 | 0.37273 | 0.358577 | 0.700425 | 0.170982 | 2.75333 | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000909 |
BRD-K60866521-001-07-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.874139 | -0.498762 | -0.021451 | 0.947981 | 0.02839 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000909 |
BRD-K60997853-001-02-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.188147 | 3.483744 | 0.438232 | 0.864706 | 1.98645 | 2.274752 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000909 |
BRD-K61192372-001-08-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.863895 | -0.832084 | 0.081877 | 0.895107 | 1.322994 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000909 |
BRD-K62008436-001-23-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.444465 | 12.225325 | 0.692795 | 0.722219 | 0.004879 | 0.005839 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000909 |
BRD-K62196610-001-01-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.737453 | -1.278729 | -0.033885 | 0.813443 | 0.615982 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000909 |
BRD-K62200014-003-10-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.870744 | 1.217933 | 0.079998 | 0.943839 | 0.148044 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000909 |
BRD-K62627508-001-01-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.164402 | 0.961805 | 0.803213 | 0.565085 | 0.06378 | 0.096541 | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000909 |
BRD-K63504947-001-14-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.231272 | -0.094174 | -0.047779 | 1 | 24.383846 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000909 |
BRD-K63712959-001-01-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.828626 | -6.447057 | 0.195042 | 0.866217 | 1.189946 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000909 |
BRD-K64052750-001-22-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.858275 | -1.095339 | -0.017434 | 0.984049 | 0.001309 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000909 |
BRD-K64881305-001-03-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.27323 | 1.693503 | 0.494872 | 0.419649 | 0.004216 | 0.006725 | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000909 |
BRD-K66175015-001-12-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.019003 | 0.097033 | -0.01073 | 1 | 0.151031 | null | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000909 |
BRD-K67844266-003-01-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.711742 | 0.440997 | -0.016962 | 0.796655 | 0.005597 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000909 |
BRD-K69001009-001-02-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.52635 | 0.277793 | 0.251603 | 0.781335 | 0.14728 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000909 |
BRD-K69694239-001-02-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.220188 | 4.604606 | 0.67773 | 0.809159 | 0.930165 | 1.055137 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000909 |
BRD-K69776681-001-03-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.258445 | 9.083263 | 0.518216 | 0.628501 | 0.077368 | 0.083819 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000909 |
BRD-K70301465-001-05-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.961906 | -0.078519 | -0.004378 | 0.981751 | 0.026505 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000909 |
BRD-K70401845-001-15-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.107826 | 5.569247 | 0.02688 | 1 | 5.211693 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000909 |
BRD-K73838513-003-05-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | -0.088476 | 3.448941 | 0.498546 | 0.959795 | 7.718492 | 7.362433 | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000909 |
BRD-K74514084-003-09-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.809129 | 7.409776 | 0.32482 | 0.937695 | 0.420947 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000909 |
BRD-K76239644-001-02-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.78677 | -7.480562 | 0.16783 | 0.891239 | 0.086116 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000909 |
BRD-K76674262-001-03-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.153423 | 1.253924 | 0.785761 | 0.472148 | 0.023373 | 0.031307 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000909 |
BRD-K76908866-001-07-6 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.010101 | -0.207453 | -0.004006 | 1 | 0.045981 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000909 |
BRD-K77625799-001-07-7 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.162965 | -1.903817 | 0.083888 | 1 | 1.16658 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000909 |
BRD-K78431006-001-15-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.103054 | 6.470115 | 0.765087 | 0.852318 | 2.023284 | 2.096733 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000909 |
BRD-K79254416-001-21-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.685038 | -1.103796 | -0.147118 | 0.948066 | 0.00255 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000909 |
BRD-K81016934-001-02-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.323046 | -0.197215 | -0.069875 | 1 | 0.028956 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000909 |
BRD-K81418486-001-44-2 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.143399 | 0.286731 | 0.13741 | 0.625499 | 0.216102 | 0.702425 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000909 |
BRD-K81473043-001-19-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.235983 | 1.054284 | 0.490841 | 0.821605 | 0.070985 | 0.130084 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000909 |
BRD-K82135108-001-04-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.483021 | 1.596118 | -0.008061 | 0.64805 | 0.013452 | 0.111992 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000909 |
BRD-K83029223-001-01-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.165462 | 7.650258 | 0.493767 | 0.50604 | 0.002 | 0.002108 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000909 |
BRD-K83988098-001-02-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.243548 | 4.335559 | 0.507871 | 0.870645 | 0.029683 | 0.034626 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000909 |
BRD-K85402309-043-01-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.154846 | 3.906716 | 0.69904 | 0.759515 | 0.63203 | 0.694925 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000909 |
BRD-K85606544-001-09-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.725971 | 0.477307 | 0.463515 | 1 | 0.371479 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000909 |
BRD-K86118762-001-01-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.933959 | -1.286936 | -0.07603 | 0.971665 | 0.039111 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-000909 |
BRD-K86972824-001-01-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.336757 | -0.849569 | 0.743647 | 0.841023 | 0.005251 | 0.001406 | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000909 |
BRD-K87737963-001-06-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.336488 | 3.303936 | 0.325447 | 0.983409 | 9.393874 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000909 |
BRD-K87782578-001-01-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.002758 | 0.798267 | 0.546303 | 0.812803 | 2.25203 | 2.267687 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000909 |
BRD-K87909389-003-03-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.283076 | 5.143745 | 0.831023 | 0.617949 | 0.056753 | 0.066757 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000909 |
BRD-K88510285-001-17-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.201232 | 5.3315 | 0.795814 | 0.565958 | 0.006817 | 0.007508 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000909 |
BRD-K89014967-001-04-3 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.734107 | 0.371931 | -0.029611 | 1 | 0.138889 | null | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000909 |
BRD-K92441787-001-04-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.870321 | -3.299832 | 0.15167 | 0.903528 | 0.833244 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000909 |
BRD-K92723993-001-17-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 30.799182 | 0.468701 | 0.034507 | 1 | 4,898,798.36503 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000909 |
BRD-K95142244-001-01-5 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.106656 | 0.644966 | 0.657555 | 0.425522 | 0.01681 | 0.024385 | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000909 |
BRD-K96123349-236-02-8 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 1.865652 | 12.138918 | 0.082408 | 1 | 6.68418 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000909 |
BRD-K98572433-001-02-9 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.994973 | -0.392809 | -0.179319 | 0.996998 | 0.282301 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000909 |
BRD-K99113996-001-02-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | -0.121631 | 0.546594 | 0.691015 | 0.681282 | 0.962272 | 0.646091 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000909 |
BRD-K99616396-001-05-1 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.767179 | -1.341355 | -0.184034 | 0.899376 | 0.040357 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-000909 |
BRD-K99749624-001-07-0 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.83929 | -2.452543 | 0.061598 | 0.942381 | 0.019786 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000909 |
BRD-M97302542-001-04-4 | ACH-000909 | JHUEM2_ENDOMETRIUM | MTS010 | 1 | 0.960427 | -0.012726 | -0.024923 | 0.975933 | 79,242,536,863,520.98 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000909 |
BRD-A25234499-001-19-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 1.193985 | -1.153066 | 0.222089 | 1 | 0.028483 | null | aminoglutethimide | glucocorticoid receptor antagonist | CYP11A1, CYP19A1 | endocrinology, oncology | Cushing's syndrome, breast cancer | CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1, CCC1(CCC(=O)NC1=O)c1ccc(N)cc1 | Launched | true | ACH-000911 |
BRD-A70858459-001-01-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.766871 | 1.395334 | -0.01758 | 0.984861 | 7.819814 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000911 |
BRD-A74914197-001-02-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.381793 | 6.360594 | 0.792844 | 0.557539 | 0.000601 | 0.000754 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000911 |
BRD-K02130563-001-11-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.098588 | 0.816476 | 0.858731 | 0.495404 | 0.04271 | 0.055891 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000911 |
BRD-K03390685-001-01-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.176387 | 0.522189 | 0.738064 | 0.580704 | 0.070425 | 0.162016 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000911 |
BRD-K03406345-001-21-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.454434 | 0.876371 | 0.417032 | 0.817508 | 0.41509 | 6.386083 | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000911 |
BRD-K03449891-001-08-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.250821 | 1.076534 | 0.476557 | 0.757025 | 0.443204 | 0.846374 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000911 |
BRD-K03765900-001-01-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.047766 | 0.546887 | 0.609886 | 0.585274 | 0.160894 | 0.19332 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000911 |
BRD-K05804044-001-18-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.455089 | 1.038994 | 0.490168 | 0.852974 | 0.778054 | 7.913181 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000911 |
BRD-K06814349-304-02-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.287557 | 3.360045 | 0.805197 | 0.766652 | 0.41645 | 0.537261 | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000911 |
BRD-K08109215-001-06-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.688522 | -0.784541 | 0.222691 | 0.948044 | 0.002027 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000911 |
BRD-K08542803-001-02-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.095441 | 7.163054 | 0.788682 | 0.688239 | 0.352688 | 0.363272 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000911 |
BRD-K08547377-001-04-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.103442 | 1.818581 | 0.843567 | 0.437184 | 0.022589 | 0.02566 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000911 |
BRD-K08703257-001-13-9 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.806599 | 4.487958 | 0.148584 | 0.836124 | 0.002683 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000911 |
BRD-K08799216-001-05-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.218611 | 0.79815 | 0.752 | 0.41563 | 0.00584 | 0.012002 | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000911 |
BRD-K09951645-001-11-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.835881 | 0.382425 | 0.069943 | 0.929897 | 0.206919 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000911 |
BRD-K11630072-001-13-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.308924 | 3.608035 | 0.678253 | 0.884576 | 1.978829 | 2.583417 | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000911 |
BRD-K12343256-001-14-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.393028 | 1.837065 | 0.702522 | 0.59118 | 0.014473 | 0.033504 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000911 |
BRD-K13049116-001-04-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.337947 | 4.313194 | 0.711553 | 0.812595 | 0.641165 | 0.832573 | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000911 |
BRD-K13390322-001-06-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.105414 | 7.118366 | 0.761682 | 0.828035 | 1.548182 | 1.600541 | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000911 |
BRD-K13514097-001-04-6 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | -0.018304 | 0.08039 | 0.140447 | 0.408935 | 0.00131 | 0.000837 | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000911 |
BRD-K13662825-001-07-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.079177 | 7.876021 | 0.653228 | 0.58439 | 0.031355 | 0.032049 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000911 |
BRD-K14109347-001-03-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.756226 | -1.089491 | -0.072985 | 0.928986 | 0.009876 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000911 |
BRD-K15179879-001-03-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.110539 | 2.130952 | 0.811915 | 0.387678 | 0.012538 | 0.014097 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000911 |
BRD-K15600710-066-05-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.125932 | 1.640344 | 0.916302 | 0.540295 | 0.059612 | 0.071147 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000911 |
BRD-K16730910-001-10-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.651119 | 1.061746 | 0.033147 | 0.899323 | 0.638212 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000911 |
BRD-K17555800-003-02-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.804 | 0.600157 | 0.141555 | 0.907506 | 0.105866 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000911 |
BRD-K17610631-001-03-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.663815 | 1.295588 | 0.098857 | 0.856115 | 0.152617 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000911 |
BRD-K17743125-001-08-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.018429 | 1.071885 | 0.809525 | 0.715611 | 0.629566 | 0.652015 | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000911 |
BRD-K17894950-001-14-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.963337 | -0.035795 | -0.102397 | 0.979202 | 153.571152 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000911 |
BRD-K18961567-001-01-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.300462 | 0.842213 | 0.277409 | 0.799591 | 0.696911 | 2.074265 | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000911 |
BRD-K19540840-001-09-4 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.718445 | 0.279617 | 0.147068 | 0.865671 | 0.113829 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000911 |
BRD-K19687926-001-04-1 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.02738 | 0.344317 | 0.484379 | 0.658251 | 0.679412 | 0.800134 | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000911 |
BRD-K22064724-001-01-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.009361 | 0.626639 | 0.696135 | 0.586351 | 0.189122 | 0.194914 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000911 |
BRD-K22822991-001-02-3 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.757855 | 0.22976 | 0.092139 | 0.856094 | 0.012553 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000911 |
BRD-K23228615-001-02-8 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.0073 | 0.53902 | 0.894282 | 0.577036 | 0.17987 | 0.184845 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000911 |
BRD-K23984367-001-07-5 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.457438 | 0.810784 | 0.382907 | 0.760989 | 0.142475 | 2.974199 | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000911 |
BRD-K26026438-001-01-0 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.595711 | 0.41348 | 0.342382 | 0.849074 | 0.401625 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000911 |
BRD-K26657438-001-15-2 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.855526 | 7.828256 | 0.106663 | 0.906617 | 0.018871 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000911 |
BRD-K28822270-001-03-7 | ACH-000911 | NUGC3_STOMACH | MTS010 | 1 | 0.251798 | 1.020459 | 0.624849 | 0.745292 | 0.397461 | 0.789515 | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000911 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.